Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Breast Surgery

Your Treatment Path: Observation vs. Surgery

At a Glance

A benign intraductal papilloma without abnormal cells may be monitored with follow-up imaging when symptoms are absent and imaging matches the biopsy. Atypia, bloody discharge, a lump, suspicious or mismatched imaging, or a large lesion often leads to removal by vacuum-assisted excision or surgery.

Deciding how to manage an intraductal papilloma is no longer a “one-size-fits-all” process. In the past, almost all papillomas were surgically removed. Today, doctors use a risk-stratified approach, meaning your treatment is tailored to the specific features of your biopsy and imaging results [1][2].

When Observation is an Option

If your biopsy shows a benign papilloma without atypia (abnormal cells) and your results are concordant (the biopsy matches the imaging), the risk of “upgrading” to cancer is very low [3].

Recent large-scale studies have found that for patients with no symptoms and a clear, benign biopsy, the risk of finding a hidden cancer is only about 1.4% to 1.7% in study cohorts [4][3]. Because this risk is so low, many experts now recommend active surveillance—watching the area with regular imaging—rather than surgery [3][5]. This approach is most appropriate when:

  • The lesion is small (some experts suggest less than 1 cm) [2].
  • You have no symptoms like bloody discharge or a palpable lump [6].
  • The biopsy removed a significant portion of the suspicious area [2].

Why Atypia Changes the Strategy

If your biopsy report mentions atypia (such as Atypical Ductal Hyperplasia or ADH), the management strategy shifts toward surgery [7].

Atypical cells are not cancer, but they are a “warning light.” When a papilloma contains atypia, the risk that a more serious condition may be present in the sampled area jumps to approximately 20% to 36% [1][8]. Because a needle biopsy only takes a tiny sample, doctors usually recommend a surgical excision (an open surgery to remove the entire area) to ensure nothing was missed [9][1]. Note that if your pathology shows ADH or ALH, your doctor may also recommend a formal breast cancer risk assessment or referral to a high-risk clinic to discuss your long-term screening plan.

Vacuum-Assisted Excision (VAE)

For some patients, a middle ground exists between “watching” and “surgery.” Vacuum-Assisted Excision (VAE) is a minimally invasive procedure that uses a specialized, larger biopsy needle to “vacuum” out the entire papilloma while you are awake, using local numbing [10].

  • Benefits: It leaves much less scarring than traditional surgery and can often be done in the radiology suite [10].
  • Success Rate: Studies show VAE is effective, with low recurrence rates (about 3.6% to 7.7%) [10][11].
  • Follow-up: Because there is a small chance the growth could return, doctors usually recommend imaging follow-up for at least three years after a VAE [12][11].

Treatment Decision Guide

This table summarizes the general consensus for how your care team might approach your diagnosis:

Biopsy Finding Symptoms Imaging Match Recommended Path
No Atypia None (Silent) Concordant Surveillance (under clinician-defined plan) [3]
No Atypia Bloody Discharge Concordant Excision (VAE or Surgery) to stop symptoms [6]
With Atypia Any Any Excision Commonly Recommended [1]
No Atypia Any Discordant Surgical Excision / Repeat Biopsy [5]
No Atypia Any Large Excision (Higher risk of hidden cells) [1]

Factors That Favor Removal

Even if your biopsy is benign, your doctor may still recommend removal if you have certain “risk-stratification” factors, such as:

  • A palpable mass (you can feel the lump) [1].
  • A “peripheral” location (the growth is deep in the breast rather than near the nipple) [13].
  • Imaging that looks particularly suspicious (a BI-RADS score of 4B, 4C, or 5) [1].
  • A history of breast cancer in the same breast [2].

Ultimately, the goal is to balance the need for a definitive diagnosis with the desire to avoid unnecessary surgery. Discussing your personal “risk comfort level” with your breast surgeon is the best way to finalize your plan.

Common questions in this guide

Can a benign intraductal papilloma be watched instead of removed?
Yes, active surveillance may be appropriate when the biopsy shows no atypia, the biopsy and imaging agree, the lesion is small, and you have no concerning symptoms. In selected patients, the risk of finding hidden cancer is low, but your clinician should set a schedule for follow-up imaging.
Why does atypia in a papilloma usually lead to surgery?
Atypia means abnormal cells are present; it is not cancer, but it raises the chance that a more serious condition was missed by the needle biopsy. Because the sample represents only part of the area, doctors commonly recommend removing the whole lesion for a more complete diagnosis.
What is vacuum-assisted excision for an intraductal papilloma?
Vacuum-assisted excision uses a larger, specialized needle to remove the papilloma while the breast is numbed with local anesthetic. It can cause less scarring than open surgery, but follow-up imaging is usually advised for at least three years because a small chance of recurrence remains.
What findings make removal more likely even without atypia?
A palpable lump, bloody discharge, a large or peripheral lesion, suspicious imaging such as BI-RADS 4B, 4C, or 5, a mismatch between biopsy and imaging, or prior breast cancer in the same breast may favor vacuum-assisted or surgical excision. Your clinician will weigh these findings with your symptoms and preferences.
What does it mean when the biopsy and imaging are concordant?
It means the biopsy result fits what the imaging showed, so the findings tell a consistent story. When a benign, non-atypical result is concordant, surveillance may be reasonable; discordant results commonly prompt repeat biopsy or surgical excision.
How often will I need imaging if I choose surveillance?
There is no single schedule for everyone; your breast team should set the timing based on the lesion, symptoms, and prior imaging. Follow-up may involve a mammogram or ultrasound every 6 to 12 months for several years, and new bloody discharge or a lump should be reported promptly.

Get notified when new evidence is published on intraductal papilloma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis.

    Zhang X, Liu W, Hai T, Li F

    Annals of surgical oncology 2021; (28(13)):8643-8650 doi:10.1245/s10434-021-10188-7.

    PMID: 34331160
  2. 2

    Multidisciplinary Review of Intraductal Papilloma of the Breast can Identify Patients who may Omit Surgical Excision.

    Abbassi-Rahbar S, Sack S, Larson KE, et al.

    Annals of surgical oncology 2021; (28(10)):5768-5774 doi:10.1245/s10434-021-10520-1.

    PMID: 34338925
  3. 3

    The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034).

    Nakhlis F, Baker GM, Pilewskie M, et al.

    Annals of surgical oncology 2021; (28(5)):2573-2578 doi:10.1245/s10434-020-09215-w.

    PMID: 33047246
  4. 4

    Malignant upgrade rate and associated clinicopathologic predictors for concordant intraductal papilloma without atypia: A systematic review and meta-analysis.

    Keating N, Cevik J, Hopkins D, Lippey J

    Journal of surgical oncology 2024; (129(6)):1025-1033 doi:10.1002/jso.27592.

    PMID: 38305061
  5. 5

    Papillary Neoplasms of the Breast: WHO Classification, Multimodality Imaging, and Radiologic-Pathologic Correlation.

    Thai JN, Vickery J, Boyraz B, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(8)):e240091 doi:10.1148/rg.240091.

    PMID: 40674246
  6. 6

    Management of benign papilloma without atypia diagnosed at ultrasound-guided core needle biopsy: Scoring system for predicting malignancy.

    Ahn SK, Han W, Moon HG, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2018; (44(1)):53-58 doi:10.1016/j.ejso.2017.10.214.

    PMID: 29174198
  7. 7

    Variability in the Management Recommendations Given for High-risk Breast Lesions Detected on Image-guided Core Needle Biopsy at U.S. Academic Institutions.

    Falomo E, Adejumo C, Carson KA, et al.

    Current problems in diagnostic radiology 2019; (48(5)):462-466 doi:10.1067/j.cpradiol.2018.06.004.

    PMID: 30075881
  8. 8

    Upgrade rates of intraductal papilloma with and without atypia diagnosed on core needle biopsy and clinicopathologic predictors.

    Corbin H, Bomeisl P, Amin AL, et al.

    Human pathology 2022; (128()):90-100 doi:10.1016/j.humpath.2022.07.012.

    PMID: 35863513
  9. 9

    Management of High-Risk Breast Lesions: A Comprehensive Update.

    Zamora KW, Komforti MK, Vorhis EB, et al.

    Journal of breast imaging 2026; (8(5)):477-494 doi:10.1093/jbi/wbag034.

    PMID: 42490060
  10. 10

    Benign Breast Papilloma without Atypia: Outcomes of Surgical Excision versus US-guided Directional Vacuum-assisted Removal or US Follow-up.

    Choi HY, Kim SM, Jang M, et al.

    Radiology 2019; (293(1)):72-80 doi:10.1148/radiol.2019190096.

    PMID: 31429678
  11. 11

    Ultrasound-Guided Vacuum-Assisted Excision to Treat Intraductal Papilloma.

    He P, Lei YT, Chen W, et al.

    World journal of surgery 2023; (47(3)):699-706 doi:10.1007/s00268-022-06735-2.

    PMID: 36624311
  12. 12

    Breast papillary lesions diagnosed and treated using ultrasound-guided vacuum-assisted excision.

    Li X, Gao H, Xu M, et al.

    BMC surgery 2020; (20(1)):204 doi:10.1186/s12893-020-00869-7.

    PMID: 32933518
  13. 13

    Treatment Strategy for Breast Benign Intraductal Papilloma: A Meta-Analysis.

    Lou C, Wang W, Zhou B

    Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 2024; (43(3)):39-49 doi:10.1615/JEnvironPatholToxicolOncol.2024052888.

    PMID: 38608144

This page is for informational purposes only and does not constitute medical advice. Your breast surgeon should interpret your biopsy and imaging results and discuss whether surveillance, VAE, or surgery is appropriate for you.